Pyridam Farma (PYFA) to Boost Revenue by Focusing on Consumer Health and Beauty in 2025
Jakarta, February 10, 2025 – PT Pyridam Farma Tbk (PYFA) continues to develop innovative strategies and enhance its capabilities to remain one of the leading pharmaceutical industries. With a strong portfolio of prescription drugs, PYFA will now drive revenue growth by focusing on the consumer health and beauty sectors in 2025.
Citing data from Statistics Indonesia and the Permara Institute for Economic Research, health trends in the consumer health sector have increased since the COVID-19 pandemic. People have become more focused on preventive treatments. Meanwhile, for the beauty industry, Deputy Minister of Industry Faisol Riza said at the opening of a beauty exhibition in Jakarta in November 2024, “The national cosmetics industry is showing promising growth, with revenue reaching USD 8.09 billion in 2023 and projected to increase to USD 9.17 billion in 2024.”
From a commercial perspective, this is a potential opportunity for PYFA, which already has the capacity and capabilities. PYFA has a business unit called PYFAHEALTH, a business line focused on vitamin and supplement products. PYFA also has a business unit launched in 2024 called PYFABEAUTY, a beauty consumer product business line in collaboration with CNT Dream Korea, a South Korean original design manufacturer (ODM) of beauty products.
After excelling and having a strong market share in prescription drugs, PYFA will drive revenue growth by focusing on developing PYFAHEALTH. PYFAHEALTH is committed to continuing to deliver products that are not only curative but also preventive and innovative, and able to provide added value to patients and consumers. With a strong product portfolio, PYFAHEALTH is making breakthroughs in the market. Some of its top portfolio products include the launch of Syalox, a pioneer of oral hyaluronic acid in Indonesia that has a function to maintain the health of joints and body tissues.
Chief Commercial Officer, Antes Eko Prasetio said, “In an effort to respond to the very rapid market dynamics, PYFA is required to be able to quickly change and adapt where PYFA must be able to accelerate the development of its commercial capabilities outside of its core business in the prescription product portfolio by adding consumer healthcare and beauty portfolios, namely PYFAHEALTH and PYFABEAUTY. We hope this step can provide more benefits to the community and consumers to improve health in Indonesia.”
This strategic step is PYFA’s medium and long-term strategy to provide holistic health solutions for the community, while strengthening the company’s competitiveness in an increasingly competitive industry.
With an adaptive and innovative strategy, and supported by a large market potential, PYFA offers sustainable investment opportunities for investors. The company’s commitment to delivering high-quality products and expanding into growing market segments demonstrates positive growth prospects in the future.
About PYFA
PT Pyridam Farma Tbk (“Stock Code: PYFA”) is one of the public companies in the pharmaceutical sector and is listed on the Indonesian Stock Exchange. As a Public Company, PYFA has a local and global scale manufacturing and distribution network. PYFA has business units in prescription drugs and consumer health (OTC) drugs in various preparations such as tablets, capsules, creams, syrups, and injections; then beauty products, and medical devices. In addition, PYFA also has services such as Contract Manufacturing and an R&D Center. PYFA oversees 4 controlled subsidiaries, namely PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec.
